Core Alternative Capital’s AstraZeneca AZN Stock Holding History

Core Alternative Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-125	Closed	-$16.8K	–	355
2023 Q4	$16.8K	Hold	125	–	–	﹤0.01%	239
2023 Q3	$16.9K	Hold	125	–	–	﹤0.01%	265
2023 Q2	$17.9K	Hold	125	–	–	﹤0.01%	241
2023 Q1	$17.4K	Hold	125	–	–	﹤0.01%	242
2022 Q4	$16.9K	Sell	125 -45	-26%	-$5.64K	﹤0.01%	230
2022 Q3	$19K	Buy	170 +45	+36%	+$5.71K	﹤0.01%	226
2022 Q2	$17K	Hold	125	–	–	﹤0.01%	233
2022 Q1	$17K	Buy	+125	New	+$15K	﹤0.01%	223

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Core Alternative Capital's AZN Position: Q1 2024 in Review

Core Alternative Capital sold out of AstraZeneca (AZN) in Q1 2024, closing a stake of 125 shares — an estimated $16.8K sold.

Core Alternative Capital first reported a position in AZN in Q1 2022 and held it in 8 quarters. The position peaked at $19K in Q3 2022. 1,142 funds tracked by Wall St. Rank hold AZN as of Q1 2024.

Core Alternative Capital reported no remaining AstraZeneca position as of Q1 2024 after selling out during the quarter.
Core Alternative Capital sold 125 AstraZeneca shares in Q1 2024, an estimated $16.8K.
Core Alternative Capital first reported a position in AstraZeneca in Q1 2022 and held it in 8 quarters.
Core Alternative Capital's AstraZeneca position peaked at $19K in Q3 2022.
1,142 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2024.

Based on Core Alternative Capital's 13F filing for Q1 2024, filed 15 May 2024.